



Detection, Diagnostics, and Control of Respiratory Syncytial Virus (RSV)

Guest Editor:

Dr. Kazuya Shirato

Laboratory of Respiratory Viral
Vaccines, Department of Virology
III, National Institute of Infectious
Disease, Tokyo, Japan

Deadline for manuscript
submissions:

closed (20 May 2023)

Message from the Guest Editor

Dear Colleagues,

Human orthopneumovirus (respiratory syncytial virus, RSV) is a major causative agent of respiratory tract infection worldwide. The World Health Organization (WHO) planned the global surveillance of RSV based on the global influenza surveillance and response system (GISRS) in 2015 following the development of a promising vaccine candidate, and started the 1st phase pilot surveillance in 2016. Although the 2nd phase pilot surveillance was also started in 2019, details of outcomes are not available. In surveillance, the detection of RSV should be performed using real-time RT-PCR assays, and the assay developed by the Center for Disease Control and Prevention in the United States or an equivalent is recommended for accurate estimation of the disease burden. During the outbreak of SARS-CoV-2, a lot of new modality vaccines were approved and these will bring light to new promising vaccines for RSV. For the accurate validation of vaccine efficiency, the precise detection and diagnosis of RSV are critical.

For this Special Issue, we invite authors to send contributions on any aspect that may help to detect and diagnose RSV.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](#)